- Home
- TVA vs ALLO Comparison
TVA vs ALLO Comparison
Compare TVA & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVA
- ALLO
- Stock Information
- Founded
- TVA 2024
- ALLO 2017
- Country
- TVA United States
- ALLO United States
- Employees
- TVA N/A
- ALLO N/A
- Industry
- TVA
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TVA
- ALLO Health Care
- Exchange
- TVA Nasdaq
- ALLO Nasdaq
- Market Cap
- TVA 303.4M
- ALLO 363.1M
- IPO Year
- TVA 2025
- ALLO 2018
- Fundamental
- Price
- TVA $10.13
- ALLO $1.50
- Analyst Decision
- TVA
- ALLO Strong Buy
- Analyst Count
- TVA 0
- ALLO 9
- Target Price
- TVA N/A
- ALLO $8.44
- AVG Volume (30 Days)
- TVA 105.0
- ALLO 3.6M
- Earning Date
- TVA 01-01-0001
- ALLO 08-06-2025
- Dividend Yield
- TVA N/A
- ALLO N/A
- EPS Growth
- TVA N/A
- ALLO N/A
- EPS
- TVA N/A
- ALLO N/A
- Revenue
- TVA N/A
- ALLO N/A
- Revenue This Year
- TVA N/A
- ALLO N/A
- Revenue Next Year
- TVA N/A
- ALLO $199.63
- P/E Ratio
- TVA N/A
- ALLO N/A
- Revenue Growth
- TVA N/A
- ALLO N/A
- 52 Week Low
- TVA $9.99
- ALLO $0.86
- 52 Week High
- TVA $10.34
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- TVA N/A
- ALLO 62.31
- Support Level
- TVA N/A
- ALLO $1.21
- Resistance Level
- TVA N/A
- ALLO $1.31
- Average True Range (ATR)
- TVA 0.00
- ALLO 0.11
- MACD
- TVA 0.00
- ALLO 0.04
- Stochastic Oscillator
- TVA 0.00
- ALLO 63.46
About TVA Texas Ventures Acquisition III Corp Class A Ordinary Share
Texas Ventures Acquisition III Corp is a blank check company.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.